E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition.

Tobias Lange; Ursula Valentiner; Daniel Wicklein; Hanna Maar; Vera Labitzky; Ann-Kristin Brauns; Thomas Streichert; Benjamin Otto; Guido Sauter; Gerrit Wolters-Eisfeld; Kristoffer Riecken; Christian BÃ Â¶rnchen; Rainer Kiefmann; Valsamma Abraham; Horace M DeLisser; Timo Gemoll; Jens K Habermann; Udo Schumacher

Journal Article

E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition.

Lange T
Valentiner U
Wicklein D
et al.

Journal of Clinical Oncology (2016) 34(15_suppl) e23010-e23010

DOI: 10.1200/jco.2016.34.15_suppl.e23010

N/ACitations

1Readers

Get full text

Cite

CITATION STYLE

APA

Lange, T., Valentiner, U., Wicklein, D., Maar, H., Labitzky, V., Brauns, A.-K., … Schumacher, U. (2016). E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition. Journal of Clinical Oncology, 34(15_suppl), e23010–e23010. https://doi.org/10.1200/jco.2016.34.15_suppl.e23010

E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition.

Cite

Register to see more suggestions